Natalizumab treatment for multiple sclerosis

Natalizumab treatment for multiple sclerosis

Saved in:

Bibliographic Details
Main Author:	Maria Lucia Brito Ferreira
Format:	Article
Language:	English
Published:	Thieme Revinter Publicações 2014-12-01
Series:	Arquivos de Neuro-Psiquiatria
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2014001200911&lng=en&tlng=en
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers
by: Enedina Maria Lobato de Oliveira, et al.
Published: (2015-09-01)

Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients
by: Luiz Henrique da Silva Nali, et al.
Published: (2014-12-01)

Pharmacokinetic Model‐Informed Precision Dosing of Natalizumab in Multiple Sclerosis
by: Stefan P. H. van denBerg, et al.
Published: (2025-06-01)

Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile
by: Maria Celica Ysrraelit, et al.
Published: (2021-06-01)

Pyoderma gangrenosum in a patient with multiple sclerosis under natalizumab treatment: a case report
by: Kosar Kohandel, et al.
Published: (2025-04-01)

Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive
by: Yara Dadalti Fragoso, et al.
Published: (2013-10-01)

Real-World Treatment Outcomes in Black, Hispanic, Asian, and White Patients with Multiple Sclerosis Treated with Natalizumab
by: Karen Blitz-Shabbir, et al.
Published: (2025-05-01)

Impact of Natalizumab on Productivity and Ability to Work in Patients with Multiple Sclerosis in France: The TITAN Study
by: Patrick Vermersch, et al.
Published: (2025-04-01)

Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
by: Diego Cadavid, et al.
Published: (2013-01-01)

In vitro morphological profiling of T cells predicts clinical response to natalizumab therapy in patients with multiple sclerosis
by: Beatriz Chaves, et al.
Published: (2025-07-01)

[Translated article] Refractory Eosinophilic Fasciitis: Good Response to Ocrelizumab in a Patient with Multiple Sclerosis Under Treatment with Natalizumab
by: B. Vázquez Losada, et al.
Published: (2024-11-01)

Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
by: Yara Dadalti Fragoso, et al.
Published: (2016-08-01)

JCV-specific cell-based assays for PML risk assessment in lupus and multiple sclerosis patients with and without natalizumab
by: Qi Wu, et al.
Published: (2025-08-01)

Evaluating natalizumab first-line and later-line use in multiple sclerosis: a US claims database analysis
by: Robin L. Avila, et al.
Published: (2025-03-01)

Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy
by: Prosperini L, et al.
Published: (2025-04-01)

Clinical Experience with Dimethyl Fumarate and Natalizumab in Pregnant Women with Multiple Sclerosis: A Four-Patient Case Series
by: Satoshi Saito, et al.
Published: (2024-01-01)

Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4+ T Cells of Patients with Relapsing-Remitting Multiple Sclerosis
by: Maria Meira, et al.
Published: (2014-01-01)

Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
by: Molly R Perkins, et al.
Published: (2012-01-01)

Comparative effectiveness, safety and persistence of ocrelizumab versus natalizumab in multiple sclerosis: A real-world, multi-center, propensity score-matched study
by: Elena Barbuti, et al.
Published: (2025-03-01)

Comparing neuromyelitis optica and multiple sclerosis severity: is there a difference?
by: Maria Lúcia Brito Ferreira
Published: (2013-05-01)

Natalizumab-associated progressive multifocal leukoencephalopathy
by: Trevor Glenn, et al.
Published: (2025-06-01)

Alemtuzumab and Natalizumab: The Monoclonal Antibody Story Continues
by: BL Johnston, et al.
Published: (2006-01-01)

Cognitive deficits in multiple sclerosis: a systematic review Déficits cognitivos na esclerose múltipla: uma revisão sistemática
by: Maria Lúcia Brito Ferreira
Published: (2010-08-01)

A Case of Drug-Induced Liver Injury Secondary to Natalizumab
by: Phillip P. Santoiemma, et al.
Published: (2020-01-01)

Switching therapy from natalizumab to fingolimod: reduction of the washout time?
by: Julia Sánchez-Gundín, et al.
Published: (2015-09-01)

Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis
by: Vanessa Daccach Marques, et al.

Comparing neuromyelitis optica and multiple sclerosis severity: is there a difference? Comparando a neuromielite óptica e a esclerose múltipla quanto à gravidade: há diferença?
by: Maria Lúcia Brito Ferreira
Published: (2013-05-01)

Fascitis eosinofílica refractaria en un paciente con esclerosis múltiple en tratamiento con natalizumab: respuesta al ocrelizumab
by: B. Vázquez Losada, et al.
Published: (2024-11-01)

Recrudescence of Natalizumab‐Induced Pneumonitis and Peripheral Hypereosinophilia: Case Report and Literature Review
by: Gerardo Arwi, et al.
Published: (2025-04-01)

21095. TRATAMIENTO CON NATALIZUMAB DURANTE LA GESTACIÓN CON ESCLEROSIS MÚLTIPLE. EXPERIENCIA CLÍNICA CON EL PROTOCOLO NAP-30
by: Á. Valero López, et al.
Published: (2024-11-01)

Disease Course in Patients Switched from Natalizumab to Alemtuzumab: An Italian Multicenter, Prospective, Observational Study
by: Simona Malucchi, et al.
Published: (2025-05-01)

Multiple Sclerosis Disease-Modifying Treatment Algorithms: 2025 Positioning of the Portuguese Multiple Sclerosis Study Group
by: Carlos Capela, et al.
Published: (2025-05-01)

Neurorehabilitation in complex treatment of multiple sclerosis
by: I. A. Rybak, et al.
Published: (2008-12-01)

Treatment of Cognitive Impairment in Multiple Sclerosis
by: Susan H. Pierson, et al.
Published: (2006-01-01)

Antioxidant Therapies in the Treatment of Multiple Sclerosis
by: Félix Javier Jiménez-Jiménez, et al.
Published: (2024-10-01)

Olfactory dysfunction as a marker of multiple sclerosis progression
by: Maria Lucia Vellutini Pimentel

General Principles of Treatment of Multiple Sclerosis in Children
by: Shorobura M.
Published: (2014-12-01)

Exosome-based platforms for treatment of multiple sclerosis
by: Aidin Mohammadi Zonouz, et al.
Published: (2025-03-01)

The role of autophagy in the pathogenesis and treatment of multiple sclerosis
by: Giulio Righes, et al.
Published: (2025-12-01)

T–CELL VACCINE PREPARATION FOR MULTIPLE SCLEROSIS TREATMENT
by: I. P. Ivanova, et al.
Published: (2014-07-01)